Cancer Clinical Trials Information Platform in Hong Kong

  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials

Cancer Site

*in alphabetical order (Last updated on 19/2/2024)

All Cancer Type

Institution Study Title  
CUHK (ACT015) A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) Click for Details
CUHK (ACT016) An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib Click for Details
CUHK (ACT022)Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer Click for Details
CUHK (ACT030) A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation (CJDQ4433A12101) Click for Details
CUHK (ACT 011)A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors,Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Click for Details
CUHK (ACT017)A Phase 1/2, Open-Label, Multi-Center, First-in-HumanStudy of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity ofTPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3Rearrangements Click for Details
CUHK (ACT020)An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments Click for Details
CUHK (ACT027)A First in-human, phase 1/2 study of CFI-402411, hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies Click for Details
CUHK (ACT033) A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Click for Details
CUHK (ACT034) Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (Tapistry) Phase II Platform Trial Click for Details
CUHK (ACT036) A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with tislelizumab in patients with select advanced cancers Click for Details
CUHK (ACT037) A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene Click for Details
HKU (UW 19-565) Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients Click for Details

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.